Collegium Pharmaceutical, Inc.
Symbol: COLL
NASDAQ
37.51
USDMarkedspris i dag
25.1608
P/E-forhold
1.5484
PEG Ratio
1.20B
MRK Cap
- 0.00%
DIV Udbytte
Collegium Pharmaceutical, Inc. (COLL) Årsregnskaber
Balance
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 1210.06 | 310.5 | 173.7 | 186.4 | |||||||||||
balance-sheet.row.short-term-investments | 159.35 | 71.6 | 0 | 0 | |||||||||||
balance-sheet.row.net-receivables | 707.98 | 179.5 | 183.1 | 105.8 | |||||||||||
balance-sheet.row.inventory | 125.38 | 32.3 | 46.5 | 17.4 | |||||||||||
balance-sheet.row.other-current-assets | 51.76 | 0.1 | 16.7 | 0 | |||||||||||
balance-sheet.row.total-current-assets | 2110.28 | 537.6 | 420 | 315.5 | |||||||||||
balance-sheet.row.property-plant-equipment-net | 94.93 | 22 | 26.4 | 27.1 | |||||||||||
balance-sheet.row.goodwill | 535.43 | 133.9 | 133.7 | 0 | |||||||||||
balance-sheet.row.intangible-assets | 1900.47 | 421.7 | 567.5 | 268.7 | |||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 2435.9 | 555.6 | 701.2 | 268.7 | |||||||||||
balance-sheet.row.long-term-investments | 3.52 | 1 | 2.5 | 2.5 | |||||||||||
balance-sheet.row.tax-assets | 100.57 | 26.3 | 23.9 | 78 | |||||||||||
balance-sheet.row.other-non-current-assets | 3.89 | 0.8 | 0.1 | 0.1 | |||||||||||
balance-sheet.row.total-non-current-assets | 2638.81 | 605.7 | 754.1 | 376.5 | |||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.total-assets | 4749.1 | 1143.3 | 1174.1 | 692.1 | |||||||||||
balance-sheet.row.account-payables | 17.76 | 8.7 | 39.6 | 33.4 | |||||||||||
balance-sheet.row.short-term-debt | 737.3 | 184.3 | 163.6 | 49.2 | |||||||||||
balance-sheet.row.tax-payables | 21.59 | 7.1 | 4.4 | 3.2 | |||||||||||
balance-sheet.row.long-term-debt-total | 2223.97 | 490 | 709.2 | 258.8 | |||||||||||
Deferred Revenue Non Current | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | |||||||||||
balance-sheet.row.other-current-liab | 1015.23 | 264.9 | 66.9 | 147.8 | |||||||||||
balance-sheet.row.total-non-current-liabilities | 2223.97 | 490 | 709.2 | 258.8 | |||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.capital-lease-obligations | 29.98 | 7.1 | 8.2 | 8.8 | |||||||||||
balance-sheet.row.total-liab | 3994.26 | 947.9 | 979.3 | 489.1 | |||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.common-stock | 0.15 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.retained-earnings | -1082.85 | -233.2 | -281.3 | -256.3 | |||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | -0.08 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.other-total-stockholders-equity | 1837.62 | 428.6 | 476.1 | 459.2 | |||||||||||
balance-sheet.row.total-stockholders-equity | 754.84 | 195.4 | 194.8 | 202.9 | |||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 4749.1 | 1143.3 | 1174.1 | 692.1 | |||||||||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.total-equity | 754.84 | 195.4 | 194.8 | 202.9 | |||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 4749.1 | - | - | - | |||||||||||
Total Investments | 161.9 | 71.6 | 2.5 | 2.5 | |||||||||||
balance-sheet.row.total-debt | 2961.26 | 674.3 | 872.8 | 258.8 | |||||||||||
balance-sheet.row.net-debt | 1910.56 | 435.3 | 699.1 | 72.3 |
Pengestrømsopgørelse
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 48.16 | 48.2 | -25 | 71.5 | |||||||||||
cash-flows.row.depreciation-and-amortization | 149.26 | 149.3 | 138.9 | 68.9 | |||||||||||
cash-flows.row.deferred-income-tax | -2.15 | -2.2 | -8.4 | -78 | |||||||||||
cash-flows.row.stock-based-compensation | 27.14 | 27.1 | 22.9 | 24.3 | |||||||||||
cash-flows.row.change-in-working-capital | 21.73 | 21.7 | -12.7 | 13.5 | |||||||||||
cash-flows.row.account-receivables | 3.59 | 3.6 | -21.8 | -22.5 | |||||||||||
cash-flows.row.inventory | 14.17 | 14.2 | 48.3 | -2.3 | |||||||||||
cash-flows.row.account-payables | 5.06 | 5.1 | -0.7 | -5.8 | |||||||||||
cash-flows.row.other-working-capital | 23.77 | -1.1 | -38.5 | 44.1 | |||||||||||
cash-flows.row.other-non-cash-items | 30.62 | 30.6 | 8.5 | 3.4 | |||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 274.75 | 0 | 0 | 0 | |||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | -0.46 | -0.5 | -1.6 | -1.9 | |||||||||||
cash-flows.row.acquisitions-net | -41.66 | 0 | -572.1 | 0 | |||||||||||
cash-flows.row.purchases-of-investments | -92.35 | -92.4 | 0 | 0 | |||||||||||
cash-flows.row.sales-maturities-of-investments | 22 | 22 | 0 | 0 | |||||||||||
cash-flows.row.other-investing-activites | 41.66 | 0 | 0 | 0 | |||||||||||
cash-flows.row.net-cash-used-for-investing-activites | -70.81 | -70.8 | -573.7 | -1.9 | |||||||||||
cash-flows.row.debt-repayment | -301.14 | -301.1 | -75 | -50 | |||||||||||
cash-flows.row.common-stock-issued | 1.84 | 9.1 | 11.8 | 12.7 | |||||||||||
cash-flows.row.common-stock-repurchased | -75.05 | -75 | -14.1 | -47.9 | |||||||||||
cash-flows.row.dividends-paid | -57.53 | -9.1 | 0 | -12.7 | |||||||||||
cash-flows.row.other-financing-activites | 291.69 | 236 | 514 | 8.6 | |||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | -140.18 | -140.2 | 436.7 | -89.3 | |||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.net-change-in-cash | 63.76 | 63.8 | -12.7 | 12.3 | |||||||||||
cash-flows.row.cash-at-end-of-period | 1056.4 | 240 | 176.2 | 189 | |||||||||||
cash-flows.row.cash-at-beginning-of-period | 992.64 | 176.2 | 189 | 176.7 | |||||||||||
cash-flows.row.operating-cash-flow | 274.75 | 274.7 | 124.2 | 103.6 | |||||||||||
cash-flows.row.capital-expenditure | -0.46 | -0.5 | -1.6 | -1.9 | |||||||||||
cash-flows.row.free-cash-flow | 274.29 | 274.3 | 122.6 | 101.6 |
Resultatopgørelse række
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 566.77 | 566.8 | 463.9 | 276.9 | |||||||||||
income-statement-row.row.cost-of-revenue | 240.6 | 240.6 | 254.4 | 126.3 | |||||||||||
income-statement-row.row.gross-profit | 326.17 | 326.2 | 209.5 | 150.6 | |||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||||||
income-statement-row.row.research-development | 0 | - | - | - | |||||||||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | |||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||
income-statement-row.row.other-expenses | 0 | 0 | 0 | 0 | |||||||||||
income-statement-row.row.operating-expenses | 159.21 | 159.2 | 176.2 | 128.4 | |||||||||||
income-statement-row.row.cost-and-expenses | 399.81 | 399.8 | 430.6 | 254.7 | |||||||||||
income-statement-row.row.interest-income | 15.62 | 15.6 | 1 | 0 | |||||||||||
income-statement-row.row.interest-expense | 83.34 | 83.3 | 63.2 | 21 | |||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||
income-statement-row.row.total-other-income-expensenet | -91.23 | -23.5 | 75.7 | 43.3 | |||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||||||
income-statement-row.row.other-operating-expenses | 0 | 0 | 0 | 0 | |||||||||||
income-statement-row.row.total-operating-expenses | -91.23 | -23.5 | 75.7 | 43.3 | |||||||||||
income-statement-row.row.interest-expense | 83.34 | 83.3 | 63.2 | 21 | |||||||||||
income-statement-row.row.depreciation-and-amortization | 152 | 149.3 | 138.9 | 68.9 | |||||||||||
income-statement-row.row.ebitda-caps | 331.83 | - | - | - | |||||||||||
income-statement-row.row.operating-income | 166.96 | 167 | -104.6 | -46.7 | |||||||||||
income-statement-row.row.income-before-tax | 75.73 | 75.7 | -28.8 | -3.4 | |||||||||||
income-statement-row.row.income-tax-expense | 27.58 | 27.6 | -3.8 | -74.9 | |||||||||||
income-statement-row.row.net-income | 48.16 | 48.2 | -25 | 71.5 |
Ofte stillede spørgsmål
Hvad er Collegium Pharmaceutical, Inc. (COLL) samlede aktiver?
Collegium Pharmaceutical, Inc. (COLL) samlede aktiver er 1143308000.000.
Hvad er virksomhedens årlige omsætning?
Den årlige omsætning er 286454000.000.
Hvad er virksomhedens profitmargin?
Virksomhedens profitmargin er 0.575.
Hvad er virksomhedens frie pengestrøm?
Det frie cash flow er 8.492.
Hvad er virksomhedens nettoprofitmargin?
Nettofortjenstmargenen er 0.085.
Hvad er firmaets samlede omsætning?
Den samlede omsætning er 0.295.
Hvad er Collegium Pharmaceutical, Inc. (COLL) nettoresultat (nettoindkomst)?
Nettoresultatet (nettoindkomsten) er 48155000.000.
Hvad er virksomhedens samlede gæld?
Den samlede gæld er 674283000.000.
Hvad er tallet for driftsudgifter?
Driftsudgifterne er 159208000.000.
Hvad er firmaets likviditet?
Virksomhedens likviditet er 238947000.000.